JP7369552B2 - medical patch - Google Patents
medical patch Download PDFInfo
- Publication number
- JP7369552B2 JP7369552B2 JP2019122202A JP2019122202A JP7369552B2 JP 7369552 B2 JP7369552 B2 JP 7369552B2 JP 2019122202 A JP2019122202 A JP 2019122202A JP 2019122202 A JP2019122202 A JP 2019122202A JP 7369552 B2 JP7369552 B2 JP 7369552B2
- Authority
- JP
- Japan
- Prior art keywords
- fatty acid
- adhesive
- mass
- medical patch
- acid ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001070 adhesive effect Effects 0.000 claims description 108
- 239000000853 adhesive Substances 0.000 claims description 105
- -1 acrylate ester Chemical class 0.000 claims description 94
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 63
- 239000000194 fatty acid Substances 0.000 claims description 63
- 229930195729 fatty acid Natural products 0.000 claims description 63
- 239000012790 adhesive layer Substances 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 57
- 239000007788 liquid Substances 0.000 claims description 35
- 239000000178 monomer Substances 0.000 claims description 33
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 33
- 239000010410 layer Substances 0.000 claims description 32
- 229920002554 vinyl polymer Polymers 0.000 claims description 32
- 229920001577 copolymer Polymers 0.000 claims description 28
- 230000035699 permeability Effects 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 239000003431 cross linking reagent Substances 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 13
- 239000000123 paper Substances 0.000 claims description 11
- 239000004744 fabric Substances 0.000 claims description 10
- 239000004745 nonwoven fabric Substances 0.000 claims description 8
- 239000002759 woven fabric Substances 0.000 claims description 8
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 6
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 6
- 125000005313 fatty acid group Chemical group 0.000 claims description 6
- 238000004132 cross linking Methods 0.000 claims description 5
- 238000010528 free radical solution polymerization reaction Methods 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 2
- 230000000379 polymerizing effect Effects 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 49
- 229920006243 acrylic copolymer Polymers 0.000 description 39
- 238000012360 testing method Methods 0.000 description 32
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 24
- 239000004014 plasticizer Substances 0.000 description 23
- 206010040844 Skin exfoliation Diseases 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 13
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 12
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 12
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 12
- 239000005642 Oleic acid Substances 0.000 description 12
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 12
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 12
- 206010040880 Skin irritation Diseases 0.000 description 11
- 231100000475 skin irritation Toxicity 0.000 description 11
- 230000036556 skin irritation Effects 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 150000002888 oleic acid derivatives Chemical class 0.000 description 5
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 5
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000011782 Keratins Human genes 0.000 description 4
- 108010076876 Keratins Proteins 0.000 description 4
- 206010040914 Skin reaction Diseases 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 238000004299 exfoliation Methods 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 230000035483 skin reaction Effects 0.000 description 4
- 231100000430 skin reaction Toxicity 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 3
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 description 3
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004018 acid anhydride group Chemical group 0.000 description 3
- 239000002390 adhesive tape Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 125000003700 epoxy group Chemical group 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 239000001593 sorbitan monooleate Substances 0.000 description 3
- 229940035049 sorbitan monooleate Drugs 0.000 description 3
- 235000011069 sorbitan monooleate Nutrition 0.000 description 3
- FKTHNVSLHLHISI-UHFFFAOYSA-N 1,2-bis(isocyanatomethyl)benzene Chemical compound O=C=NCC1=CC=CC=C1CN=C=O FKTHNVSLHLHISI-UHFFFAOYSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920001342 Bakelite® Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000004637 bakelite Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940060384 isostearyl isostearate Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000002653 magnetic therapy Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000005488 sandblasting Methods 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- SBJCUZQNHOLYMD-UHFFFAOYSA-N 1,5-Naphthalene diisocyanate Chemical compound C1=CC=C2C(N=C=O)=CC=CC2=C1N=C=O SBJCUZQNHOLYMD-UHFFFAOYSA-N 0.000 description 1
- BBBHAOOLZKQYKX-QXMHVHEDSA-N 16-methylheptadecyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCCCCCCCCCCCCCCC(C)C BBBHAOOLZKQYKX-QXMHVHEDSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- FWWXYLGCHHIKNY-UHFFFAOYSA-N 2-ethoxyethyl prop-2-enoate Chemical compound CCOCCOC(=O)C=C FWWXYLGCHHIKNY-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- HFCUBKYHMMPGBY-UHFFFAOYSA-N 2-methoxyethyl prop-2-enoate Chemical compound COCCOC(=O)C=C HFCUBKYHMMPGBY-UHFFFAOYSA-N 0.000 description 1
- UVRCNEIYXSRHNT-UHFFFAOYSA-N 3-ethylpent-2-enamide Chemical compound CCC(CC)=CC(N)=O UVRCNEIYXSRHNT-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- VWRHSNKTSSIMGE-UHFFFAOYSA-N 5-ethylsulfanyl-1,3,4-thiadiazol-2-amine Chemical compound CCSC1=NN=C(N)S1 VWRHSNKTSSIMGE-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000005058 Isophorone diisocyanate Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- YIVJZNGAASQVEM-UHFFFAOYSA-N Lauroyl peroxide Chemical compound CCCCCCCCCCCC(=O)OOC(=O)CCCCCCCCCCC YIVJZNGAASQVEM-UHFFFAOYSA-N 0.000 description 1
- OXPCWUWUWIWSGI-MSUUIHNZSA-N Lauryl oleate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC OXPCWUWUWIWSGI-MSUUIHNZSA-N 0.000 description 1
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 1
- CNCOEDDPFOAUMB-UHFFFAOYSA-N N-Methylolacrylamide Chemical compound OCNC(=O)C=C CNCOEDDPFOAUMB-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 229920006222 acrylic ester polymer Polymers 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000007718 adhesive strength test Methods 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- HIFVAOIJYDXIJG-UHFFFAOYSA-N benzylbenzene;isocyanic acid Chemical class N=C=O.N=C=O.C=1C=CC=CC=1CC1=CC=CC=C1 HIFVAOIJYDXIJG-UHFFFAOYSA-N 0.000 description 1
- 229960001506 brilliant green Drugs 0.000 description 1
- HXCILVUBKWANLN-UHFFFAOYSA-N brilliant green cation Chemical compound C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 HXCILVUBKWANLN-UHFFFAOYSA-N 0.000 description 1
- UTOVMEACOLCUCK-PLNGDYQASA-N butyl maleate Chemical compound CCCCOC(=O)\C=C/C(O)=O UTOVMEACOLCUCK-PLNGDYQASA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 238000010556 emulsion polymerization method Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 239000011086 glassine Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- JYTMDBGMUIAIQH-UHFFFAOYSA-N hexadecyl oleate Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC JYTMDBGMUIAIQH-UHFFFAOYSA-N 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QTDSLDJPJJBBLE-PFONDFGASA-N octyl (z)-octadec-9-enoate Chemical compound CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC QTDSLDJPJJBBLE-PFONDFGASA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 description 1
- JYTMDBGMUIAIQH-ZPHPHTNESA-N palmityl oleate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC JYTMDBGMUIAIQH-ZPHPHTNESA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920006289 polycarbonate film Polymers 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920003225 polyurethane elastomer Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 239000007870 radical polymerization initiator Substances 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010558 suspension polymerization method Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DHZWALZKPWZSMA-UHFFFAOYSA-N tetradecyl oleate Natural products CCCCCCCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC DHZWALZKPWZSMA-UHFFFAOYSA-N 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/0253—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the adhesive material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/0256—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the parametric properties of the adhesive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J11/00—Features of adhesives not provided for in group C09J9/00, e.g. additives
- C09J11/02—Non-macromolecular additives
- C09J11/06—Non-macromolecular additives organic
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J133/00—Adhesives based on homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Adhesives based on derivatives of such polymers
- C09J133/04—Homopolymers or copolymers of esters
- C09J133/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, the oxygen atom being present only as part of the carboxyl radical
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09J—ADHESIVES; NON-MECHANICAL ASPECTS OF ADHESIVE PROCESSES IN GENERAL; ADHESIVE PROCESSES NOT PROVIDED FOR ELSEWHERE; USE OF MATERIALS AS ADHESIVES
- C09J7/00—Adhesives in the form of films or foils
- C09J7/30—Adhesives in the form of films or foils characterised by the adhesive composition
- C09J7/38—Pressure-sensitive adhesives [PSA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00412—Plasters use for use with needles, tubes or catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00655—Plasters adhesive
- A61F2013/00659—Plasters adhesive polymeric base
- A61F2013/00663—Plasters adhesive polymeric base acrylic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/01—Introducing, guiding, advancing, emplacing or holding catheters
- A61M25/02—Holding devices, e.g. on the body
- A61M2025/0266—Holding devices, e.g. on the body using pads, patches, tapes or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Description
本発明は、粘着包帯や絆創膏等の皮膚表面に貼付される医療用貼付材、及びその粘着剤層の形成に好適な粘着剤組成物に関する。 The present invention relates to medical patches such as adhesive bandages and adhesive plasters that are applied to the skin surface, and adhesive compositions suitable for forming adhesive layers thereof.
粘着包帯や絆創膏等の医療用貼付材は、カテーテル等のチューブ等を皮膚表面に固定する際にも用いられる。カテーテル等の固定においては、誤って剥がれることのないように安定して固定することが必要であり、このため、用いられる医療用貼付材には、高い粘着力が優先される傾向にある。一方で、カテーテル等は、長時間の固定が必要とされる場合や、皮膚の同じ部位に繰り返し固定される場合がある。このため、カテーテル等の固定に使用される医療用貼付材には、連続貼付や繰り返し貼付された場合に、皮膚への影響が少ないことが求められている。また、肩や腰といった特定の部位に貼付される鎮痛消炎剤や、磁気治療器絆創膏等も、皮膚の同じ部位に繰り返し固定される場合があり、これ等に使用される医療用貼付材も、連続貼付や繰り返し貼付された場合の皮膚への影響が少ないことが望ましい。 Medical patches such as adhesive bandages and adhesive plasters are also used to fix tubes such as catheters to the skin surface. When fixing catheters and the like, it is necessary to stably fix them so that they do not come off accidentally, and for this reason, there is a tendency for high adhesive strength to be prioritized in the medical adhesive materials used. On the other hand, catheters and the like may need to be fixed for a long time or may be fixed repeatedly to the same site on the skin. For this reason, medical patches used for fixing catheters and the like are required to have little effect on the skin when applied continuously or repeatedly. In addition, pain-relieving anti-inflammatory drugs and magnetic therapy bandages that are applied to specific areas such as the shoulders and hips may be repeatedly fixed to the same area of the skin; It is desirable that there is little effect on the skin when applied continuously or repeatedly.
皮膚への刺激が抑えられた医療用貼付材としては、例えば特許文献１には、粘着剤として、重量平均分子量２５０万以上のアクリル酸エステル系ポリマーに、これに相溶する脂肪酸エステルを液状可塑剤として含有させた粘着剤組成物を用いた医療用貼付材が記載されている。接着性が良好なアクリル酸エステル系ポリマーを粘着剤層とし、これに相溶する脂肪酸エステルを液状可塑剤として含有させることにより、粘着剤層が可塑化されて柔らかくなり、皮膚刺激性が低減される。 For example, Patent Document 1 describes a medical patch with reduced irritation to the skin, which uses an acrylic acid ester polymer with a weight average molecular weight of 2.5 million or more and a fatty acid ester compatible therewith as a liquid plastic adhesive. A medical patch using a pressure-sensitive adhesive composition contained as an agent has been described. By using an acrylic ester polymer with good adhesive properties as the adhesive layer and containing a compatible fatty acid ester as a liquid plasticizer, the adhesive layer is plasticized and becomes soft, reducing skin irritation. Ru.
また、粘着剤層に液状可塑剤を配合した粘着剤層を備える医療用貼付材としては、例えば特許文献２には、（メタ）アクリル酸アルキルエステルを乳化重合して得られた共重合体からなるアクリル系粘着剤に、脂肪酸エステルなどの液状可塑剤を添加した粘着剤層を支持体に形成した貼付材が開示されている。 Furthermore, as a medical patch having an adhesive layer containing a liquid plasticizer, for example, Patent Document 2 discloses a copolymer obtained by emulsion polymerization of an alkyl (meth)acrylic ester. A patch is disclosed in which a pressure-sensitive adhesive layer is formed on a support by adding a liquid plasticizer such as a fatty acid ester to an acrylic pressure-sensitive adhesive.
本発明は、充分な粘着力を有しつつ、皮膚の同じ部位に繰り返し貼付された場合に皮膚への影響が小さい医療用貼付材を提供することを目的とする。 An object of the present invention is to provide a medical patch that has sufficient adhesive strength and has little effect on the skin when repeatedly applied to the same area of the skin.
本発明者らは、医療用貼付材の粘着剤層を構成するアクリル系粘着剤を、アクリル系共重合体１００質量部に対して、分子量が３５０～５５０であり、室温で液状の脂肪酸エステルを５～２５質量部含有させ、さらに、透湿度が５００ｇ／ｍ２・２４ｈ以上である支持体とすることにより、ヒト皮膚への高い粘着力を維持しつつ、角質剥離面積率が低減された医療用貼付材が得られることを見出し、本発明を完成させた。 The present inventors have determined that the acrylic adhesive constituting the adhesive layer of the medical patch has a molecular weight of 350 to 550 based on 100 parts by mass of the acrylic copolymer, and is a liquid fatty acid ester at room temperature. By containing 5 to 25 parts by mass and further having a water vapor permeability of 500 g/m 2 · 24 h or more, the medical product maintains high adhesion to human skin while reducing the exfoliated area rate of keratin. The present invention was completed based on the discovery that it is possible to obtain a medical adhesive patch for use.
すなわち、本発明は、以下の医療用貼付材を提供するものである。
［１］ 支持体と粘着剤層の積層体を備える医療用貼付材であって、
前記粘着剤層が、（メタ）アクリル酸アルキルエステルを主成分とした共重合体と、室温で液状の前記共重合体と相溶する脂肪酸エステルとを含有する粘着剤組成物からなり、
前記粘着剤組成物に含有されている前記脂肪酸エステルの質量平均分子量が３５０～５５０であり、
前記粘着剤組成物は、前記共重合体１００質量部に対して、前記脂肪酸エステルを５～２５質量部含有しており、
前記支持体の透湿度が５００ｇ／ｍ２・２４ｈ以上である、
医療用貼付材。
［２］ 前記脂肪酸エステルが、分子量３５０～５５０である単一種の脂肪酸エステルを含有する、前記［１］の医療用貼付材。
［３］ 前記共重合体が、炭素数が８～１２のアルキル基を有するアクリル酸アルキルエステルが６５～９０質量％と、アクリル酸が２～１５質量％と、酢酸ビニルが５～２５質量％と、その他のビニル単量体が０～１０質量％とが溶液重合法により重合した共重合体を、架橋剤にて架橋させたものである、前記［１］又は［２］の医療用貼付材。
［４］ 前記脂肪酸エステルが、少なくとも１個のオレイン酸残基を有する、前記［１］～［３］のいずれかの医療用貼付材。
［５］ 前記脂肪酸エステル中の脂肪酸残基が、全てオレイン酸残基である、前記［４］の医療用貼付材。
［６］ さらに、前記粘着剤層の前記支持体と接している面とは逆の面にセパレーター層を備える、前記［１］～［５］のいずれかの医療用貼付材。
［７］ 皮膚の同じ部位に繰り返し貼付される、前記［１］～［６］のいずれかの医療用貼付材。
［８］ チューブ固定用である、前記［１］～［７］のいずれかの医療用貼付材。
That is, the present invention provides the following medical patch.
[1] A medical patch comprising a laminate of a support and an adhesive layer,
The adhesive layer is made of an adhesive composition containing a copolymer mainly composed of an alkyl (meth)acrylate ester and a fatty acid ester that is liquid at room temperature and is compatible with the copolymer,
The weight average molecular weight of the fatty acid ester contained in the adhesive composition is 350 to 550,
The adhesive composition contains 5 to 25 parts by mass of the fatty acid ester based on 100 parts by mass of the copolymer,
The moisture permeability of the support is 500 g/m 2 · 24 h or more,
Medical patch.
[2] The medical patch according to [1] above, wherein the fatty acid ester contains a single type of fatty acid ester having a molecular weight of 350 to 550.
[3] The copolymer contains 65 to 90% by mass of an acrylic acid alkyl ester having an alkyl group having 8 to 12 carbon atoms, 2 to 15% by mass of acrylic acid, and 5 to 25% by mass of vinyl acetate. The medical patch according to [1] or [2] above, which is a copolymer obtained by polymerizing 0 to 10% by mass of another vinyl monomer by a solution polymerization method, and crosslinking it with a crosslinking agent. Material.
[4] The medical patch according to any one of [1] to [3] above, wherein the fatty acid ester has at least one oleic acid residue.
[5] The medical patch according to [4] above, wherein all fatty acid residues in the fatty acid ester are oleic acid residues.
[6] The medical patch according to any one of [1] to [5], further comprising a separator layer on a surface of the adhesive layer opposite to the surface in contact with the support.
[7] The medical patch according to any one of [1] to [6] above, which is repeatedly applied to the same site on the skin.
[8] The medical patch according to any one of [1] to [7] above, which is for fixing a tube.
本発明によれば、高い粘着力を維持しつつ、皮膚の同じ部位に連続貼付又は繰り返し貼付した際にも皮膚刺激が低い粘着剤組成物により粘着剤層が形成された医療用貼付材を提供することができる。 According to the present invention, there is provided a medical patch in which an adhesive layer is formed of an adhesive composition that maintains high adhesive strength and exhibits low skin irritation even when applied continuously or repeatedly to the same site on the skin. can do.
＜粘着剤組成物＞
本発明に係る医療用貼付材の粘着剤層を構成する粘着剤組成物は、（メタ）アクリル酸アルキルエステルを主成分とした共重合体と、室温（１～３０℃）で液状の脂肪酸エステルとを含有する。当該脂肪酸エステルは、粘着剤である（メタ）アクリル酸アルキルエステルを主成分とした共重合体に対して相溶であり、可塑性を付与する液状可塑剤である。
<Adhesive composition>
The adhesive composition constituting the adhesive layer of the medical patch according to the present invention comprises a copolymer mainly composed of an alkyl (meth)acrylic ester and a fatty acid ester that is liquid at room temperature (1 to 30°C). Contains. The fatty acid ester is a liquid plasticizer that is compatible with a copolymer mainly composed of an alkyl (meth)acrylate, which is an adhesive, and imparts plasticity.
（（メタ）アクリル酸アルキルエステルを主成分とした共重合体）
（メタ）アクリル酸アルキルエステルを主成分とした共重合体（以下、「アクリル系共重合体」ということがある。）とは、共重合体を構成する全構成単位に対する５０％以上が（メタ）アクリル酸アルキルエステルに由来する構成単位である共重合体を意味する。なお、本発明及び本願明細書において、（メタ）アクリル酸アルキルエステルとは、「アクリル酸アルキルエステル及び／又はメタクリル酸アルキルエステル」を表す。
(Copolymer mainly composed of (meth)acrylic acid alkyl ester)
A copolymer containing (meth)acrylic acid alkyl ester as a main component (hereinafter sometimes referred to as "acrylic copolymer") means that 50% or more of the total structural units constituting the copolymer are (meth) ) means a copolymer that is a structural unit derived from an acrylic acid alkyl ester. In addition, in the present invention and the present specification, (meth)acrylic acid alkyl ester represents "acrylic acid alkyl ester and/or methacrylic acid alkyl ester."
当該共重合体の構成単位が由来する（メタ）アクリル酸アルキルエステルとしては、アルキル基部分の炭素数が１～１８である（メタ）アクリル酸アルキルエステルが好ましい。具体的には、（メタ）アクリル酸メチル、（メタ）アクリル酸エチル、（メタ）アクリル酸ｎ－ブチル、（メタ）アクリル酸イソブチル、（メタ）アクリル酸ｔ－ブチル、（メタ）アクリル酸ｎ－ヘキシル、（メタ）アクリル酸ｎ－オクチル、（メタ）アクリル酸２－エチルヘキシル、（メタ）アクリル酸イソオクチル、（メタ）アクリル酸イソノニル、（メタ）アクリル酸ｎ－デシル、（メタ）アクリル酸イソデシル、（メタ）アクリル酸ラウリル、（メタ）アクリル酸ステアリル等が挙げられる。これらの（メタ）アクリル酸アルキルエステルは、それぞれ単独で、又は２種以上を組み合わせて用いることができる。 As the (meth)acrylic acid alkyl ester from which the constituent units of the copolymer are derived, (meth)acrylic acid alkyl esters in which the alkyl group moiety has 1 to 18 carbon atoms are preferred. Specifically, methyl (meth)acrylate, ethyl (meth)acrylate, n-butyl (meth)acrylate, isobutyl (meth)acrylate, t-butyl (meth)acrylate, n-(meth)acrylate. -Hexyl, n-octyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, isooctyl (meth)acrylate, isononyl (meth)acrylate, n-decyl (meth)acrylate, isodecyl (meth)acrylate , lauryl (meth)acrylate, stearyl (meth)acrylate, and the like. These (meth)acrylic acid alkyl esters can be used alone or in combination of two or more.
本発明において用いられるアクリル系共重合体の構成単位が由来する（メタ）アクリル酸アルキルエステルとしては、炭素数が４～１８のアルキル基を有する（メタ）アクリル酸アルキルエステルが好ましく、炭素数が４～１２のアルキル基を有する（メタ）アクリル酸アルキルエステルがより好ましく、炭素数が６～１２のアルキル基を有する（メタ）アクリル酸アルキルエステルがさらに好ましく、炭素数が８～１２のアルキル基を有する（メタ）アクリル酸アルキルエステルがよりさらに好ましく、（メタ）アクリル酸２－エチルヘキシル、（メタ）アクリル酸ｎ－オクチル、（メタ）アクリル酸イソオクチル、又は（メタ）アクリル酸イソノニルが特に好ましい。 The (meth)acrylic acid alkyl ester from which the constituent units of the acrylic copolymer used in the present invention are derived is preferably a (meth)acrylic acid alkyl ester having an alkyl group having 4 to 18 carbon atoms; (Meth)acrylic acid alkyl esters having 4 to 12 alkyl groups are more preferred, (meth)acrylic acid alkyl esters having 6 to 12 carbon atoms are even more preferred, and alkyl groups having 8 to 12 carbon atoms are preferred. Even more preferred are (meth)acrylic acid alkyl esters having the following: 2-ethylhexyl (meth)acrylate, n-octyl (meth)acrylate, isooctyl (meth)acrylate, or isononyl (meth)acrylate are particularly preferred.
本発明において用いられるアクリル系共重合体としては、（メタ）アクリル酸アルキルエステルに由来する構成単位として、アルキル基部分の炭素数が４～１８である（メタ）アクリル酸アルキルエステルに由来する構成単位を少なくとも１種類含むものが好ましい。例えば、（メタ）アクリル酸アルキルエステルに由来する構成単位として、アルキル基部分の炭素数が４～１８である（メタ）アクリル酸アルキルエステルに由来する構成単位のみを有している共重合体であってもよく、アルキル基部分の炭素数が４～１８である（メタ）アクリル酸アルキルエステルに由来する構成単位と、これ以外の（メタ）アクリル酸アルキルエステルに由来する構成単位との両方を含む共重合体であってもよい。 The acrylic copolymer used in the present invention has a structure derived from an alkyl (meth)acrylate in which the alkyl group has 4 to 18 carbon atoms as a structural unit derived from an alkyl (meth)acrylate. Those containing at least one type of unit are preferred. For example, a copolymer having only a structural unit derived from a (meth)acrylic acid alkyl ester in which the alkyl group portion has 4 to 18 carbon atoms. Both the structural unit derived from a (meth)acrylic acid alkyl ester whose alkyl group moiety has 4 to 18 carbon atoms and the structural unit derived from another (meth)acrylic acid alkyl ester may be present. It may also be a copolymer containing
本発明において用いられるアクリル系共重合体としては、（メタ）アクリル酸アルキルエステルに由来する構成単位のみからなる共重合体であってもよく、その他の重合性化合物に由来する構成単位を含む共重合体であってもよい。その他の重合性化合物としては、ビニル基を有する化合物（ビニル単量体）が挙げられる。 The acrylic copolymer used in the present invention may be a copolymer consisting only of structural units derived from (meth)acrylic acid alkyl ester, or a copolymer containing structural units derived from other polymerizable compounds. It may also be a polymer. Other polymerizable compounds include compounds having vinyl groups (vinyl monomers).
当該ビニル単量体としては、例えば、水酸基、カルボキシル基、酸無水物基、アミド基、アミノ基、エポキシ基、アルコキシ基、アシル基、シアノ基、アリール基、複素環基等の官能基を有するビニル単量体が挙げられる。水酸基を有するビニル単量体としては、（メタ）アクリル酸２－ヒドロキシエチル、（メタ）アクリル酸３－ヒドロキシプロピル、（メタ）アクリル酸４－ヒドロキシブチル等の水酸基を有する（メタ）アクリル酸エステル等が挙げられる。カルボキシル基又は酸無水物基を有するビニル単量体としては、アクリル酸、メタクリル酸、マレイン酸、無水マレイン酸、イタコン酸、マレイン酸モノブチル等が挙げられる。アミド基を有するビニル単量体としては、アクリルアミド、ジメチルアクリルアミド、ジエチルアクリルアミド、メタクリルアミド、Ｎ－メチロールアクリルアミド等が挙げられる。アミノ基を有するビニル単量体としては、ジメチルアミノエチルアクリレート等が挙げられる。エポキシ基を有するビニル単量体としては、アクリル酸グリシジル、メタクリル酸グリシジル等が挙げられる。アルコキシ基を有するビニル単量体としては、アクリル酸２－メトキシエチル、アクリル酸エトキシエチル等のアクリル酸アルコキシアルキルエステル等が挙げられる。アシル基を有するビニル単量体としては、酢酸ビニル等のビニルエステル等が挙げられる。シアノ基を有するビニル単量体としては、アクリロニトリル、メタクリロニトリル等の不飽和ニトリル等が挙げられる。アリール基を有するビニル単量体としては、スチレン等のビニル芳香族化合物等が挙げられる。複素環基を有するビニル単量体としては、Ｎ－ビニルピロリドン等のピロリドン環を有するビニル単量体等が挙げられる。これらのビニル単量体は、それぞれ単独で、又は２種以上を組み合わせて使用することができる。 The vinyl monomer has a functional group such as a hydroxyl group, a carboxyl group, an acid anhydride group, an amide group, an amino group, an epoxy group, an alkoxy group, an acyl group, a cyano group, an aryl group, a heterocyclic group, etc. Examples include vinyl monomers. Examples of vinyl monomers having a hydroxyl group include (meth)acrylic acid esters having a hydroxyl group such as 2-hydroxyethyl (meth)acrylate, 3-hydroxypropyl (meth)acrylate, and 4-hydroxybutyl (meth)acrylate. etc. Examples of the vinyl monomer having a carboxyl group or an acid anhydride group include acrylic acid, methacrylic acid, maleic acid, maleic anhydride, itaconic acid, and monobutyl maleate. Examples of the vinyl monomer having an amide group include acrylamide, dimethylacrylamide, diethylacrylamide, methacrylamide, and N-methylolacrylamide. Examples of the vinyl monomer having an amino group include dimethylaminoethyl acrylate and the like. Examples of the vinyl monomer having an epoxy group include glycidyl acrylate and glycidyl methacrylate. Examples of the vinyl monomer having an alkoxy group include alkoxyalkyl acrylates such as 2-methoxyethyl acrylate and ethoxyethyl acrylate. Examples of the vinyl monomer having an acyl group include vinyl esters such as vinyl acetate. Examples of the vinyl monomer having a cyano group include unsaturated nitriles such as acrylonitrile and methacrylonitrile. Examples of the vinyl monomer having an aryl group include vinyl aromatic compounds such as styrene. Examples of the vinyl monomer having a heterocyclic group include vinyl monomers having a pyrrolidone ring such as N-vinylpyrrolidone. These vinyl monomers can be used alone or in combination of two or more.
本発明において用いられるアクリル系共重合体としては、（メタ）アクリル酸アルキルエステルと、その他のビニル単量体との共重合体であることが好ましく、当該その他のビニル単量体に、水酸基、カルボキシル基、酸無水物基、アミド基、アミノ基、エポキシ基、及びアルコキシ基からなる群より選ばれる少なくとも１種の官能基を有するビニル単量体（以下、「ビニル単量体（Ａ）」ということがある。）が少なくとも１種含まれている共重合体であることがより好ましく、さらに、官能基を有さないビニル単量体（以下、「ビニル単量体（Ｂ）」ということがある。）が少なくとも１種含まれている共重合体であることが好ましい。 The acrylic copolymer used in the present invention is preferably a copolymer of a (meth)acrylic acid alkyl ester and another vinyl monomer, and the other vinyl monomer has a hydroxyl group, A vinyl monomer having at least one functional group selected from the group consisting of a carboxyl group, an acid anhydride group, an amide group, an amino group, an epoxy group, and an alkoxy group (hereinafter referred to as "vinyl monomer (A)") It is more preferable that the copolymer is a copolymer containing at least one kind of vinyl monomer (B), which has no functional group (hereinafter referred to as "vinyl monomer (B)"). It is preferable that the copolymer contains at least one type of .).
本発明において用いられるアクリル系共重合体としては、炭素数が４～１８、好ましくは８～１２のアルキル基を有するアクリル酸アルキルエステルが５５～９５質量％、好ましくは６０～９５質量％、より好ましくは６５～９０質量％；ビニル単量体（Ａ）が１～２５質量％、好ましくは１～２０質量％、より好ましくは２～１５質量％；ビニル単量体（Ａ）以外のビニル単量体が０～４０質量％、好ましくは０～３０質量％、より好ましくは０～２５質量％；及び、その他のビニル単量体が０～１０質量％；の共重合体であることが好ましく、炭素数が４～１８、好ましくは８～１２のアルキル基を有するアクリル酸アルキルエステルが５５～９５質量％、好ましくは６０～９５質量％、より好ましくは６５～９０質量％；ビニル単量体（Ａ）が１～２５質量％、好ましくは１～２０質量％、より好ましくは２～１５質量％；ビニル単量体（Ｂ）が０～４０質量％、好ましくは３～３０質量％、より好ましくは５～２５質量％；及び、その他のビニル単量体が０～１０質量％；の共重合体であることがより好ましい。なかでも、ビニル単量体（Ａ）がアクリル酸であり、ビニル単量体（Ｂ）が酢酸ビニルであることが特に好ましく、炭素数が４～１８、好ましくは８～１２のアルキル基を有するアクリル酸アルキルエステルが５５～９５質量％、好ましくは６０～９５質量％、より好ましくは６５～９０質量％；アクリル酸が１～２５質量％、好ましくは１～２０質量％、より好ましくは２～１５質量％；酢酸ビニルが０～４０質量％、好ましくは３～３０質量％、より好ましくは５～２５質量％；及び、その他のビニル単量体が０～１０質量％；の共重合体であることがより好ましい。このような共重合組成を有するアクリル系共重合体を粘着剤として用いることにより、粘着剤層が薄くても適度の粘着性を示し、その他の特性にも優れた粘着剤層を形成することが容易となる。 The acrylic copolymer used in the present invention includes 55 to 95% by mass, preferably 60 to 95% by mass of an acrylic acid alkyl ester having an alkyl group having 4 to 18 carbon atoms, preferably 8 to 12 carbon atoms, and more preferably 60 to 95% by mass. Preferably 65 to 90% by mass; vinyl monomer (A) 1 to 25% by mass, preferably 1 to 20% by mass, more preferably 2 to 15% by mass; It is preferably a copolymer containing 0 to 40% by mass, preferably 0 to 30% by mass, more preferably 0 to 25% by mass, and 0 to 10% by mass of other vinyl monomers. , 55 to 95% by mass of acrylic acid alkyl ester having an alkyl group having 4 to 18 carbon atoms, preferably 8 to 12 carbon atoms, preferably 60 to 95% by mass, more preferably 65 to 90% by mass; vinyl monomer (A) is 1 to 25% by weight, preferably 1 to 20% by weight, more preferably 2 to 15% by weight; vinyl monomer (B) is 0 to 40% by weight, preferably 3 to 30% by weight, and more It is preferably a copolymer containing 5 to 25% by mass; and more preferably 0 to 10% by mass of other vinyl monomers. Among these, it is particularly preferable that the vinyl monomer (A) is acrylic acid and the vinyl monomer (B) is vinyl acetate, and has an alkyl group having 4 to 18 carbon atoms, preferably 8 to 12 carbon atoms. 55-95% by weight of acrylic acid alkyl ester, preferably 60-95% by weight, more preferably 65-90% by weight; 1-25% by weight of acrylic acid, preferably 1-20% by weight, more preferably 2-20% by weight 15% by mass; 0 to 40% by mass of vinyl acetate, preferably 3 to 30% by mass, more preferably 5 to 25% by mass; and 0 to 10% by mass of other vinyl monomers. It is more preferable that there be. By using an acrylic copolymer having such a copolymerization composition as an adhesive, it is possible to form an adhesive layer that exhibits appropriate adhesiveness even if the adhesive layer is thin and has excellent other properties. It becomes easier.
本発明において用いられるアクリル系共重合体の重量平均分子量は、好ましくは３００，０００～１，０００，０００、より好ましくは４５０，０００～６５０，０００である。アクリル系共重合体の重量平均分子量を上記範囲内とすることによって、凝集性、粘着力、他成分との混合作業性、他成分との親和性などをバランスさせることができる。分子量が３００，０００を下回ると凝集性が低下するため、剥離時に皮膚への糊残りを生ずる恐れがある。分子量が１，０００，０００を上回ると、製造時の取り扱い性に劣る。アクリル系共重合体の重量平均分子量は、ゲルパーミエーションクロマトグラフィ（ＧＰＣ）法により、標準ポリスチレン換算値として求めた値である。 The weight average molecular weight of the acrylic copolymer used in the present invention is preferably 300,000 to 1,000,000, more preferably 450,000 to 650,000. By setting the weight average molecular weight of the acrylic copolymer within the above range, cohesiveness, adhesive strength, workability of mixing with other components, affinity with other components, etc. can be balanced. When the molecular weight is less than 300,000, cohesiveness decreases, which may result in adhesive residue on the skin when peeled off. When the molecular weight exceeds 1,000,000, handling during production is poor. The weight average molecular weight of the acrylic copolymer is a value determined as a standard polystyrene equivalent value by gel permeation chromatography (GPC).
本発明において用いられるアクリル系共重合体は、一般に、ラジカル重合させることにより合成することができる。当該アクリル系共重合体は、溶液重合法、懸濁重合法、又は乳化重合法により製造することができるが、良好な粘着特性が得られ易い点で、溶液重合法が好ましい。重合開始剤としては、ベンゾイルパーオキサイド、ラウロイルパーオキサイドなどの有機過酸化物；アゾビスイソブチロニトリルなどのアゾ系開始剤；などが挙げられる。全単量体に対して、０．１～３質量％程度の割合でラジカル重合開始剤を加え、窒素気流下、４０～９０℃程度の温度で、数時間から数十時間撹拌して共重合させる。溶液重合法では、溶媒として、酢酸エチル、アセトン、トルエン、これらの混合物などが汎用されている。 The acrylic copolymer used in the present invention can generally be synthesized by radical polymerization. The acrylic copolymer can be produced by a solution polymerization method, a suspension polymerization method, or an emulsion polymerization method, but the solution polymerization method is preferred since good adhesive properties are easily obtained. Examples of the polymerization initiator include organic peroxides such as benzoyl peroxide and lauroyl peroxide; azo initiators such as azobisisobutyronitrile; and the like. A radical polymerization initiator is added at a ratio of about 0.1 to 3% by mass based on the total monomers, and copolymerization is carried out by stirring at a temperature of about 40 to 90°C for several hours to several tens of hours under a nitrogen stream. let In the solution polymerization method, ethyl acetate, acetone, toluene, and mixtures thereof are commonly used as solvents.
（架橋及び架橋剤）
本発明において用いられる粘着剤組成物は、架橋剤を含有していてもよい。当該粘着剤組成物が架橋剤を含有する場合には、当該粘着剤組成物中のアクリル系共重合体を架橋処理して粘着剤層を形成することによって、粘着剤層の凝集力を向上させることができる。
(Crosslinking and crosslinking agent)
The adhesive composition used in the present invention may contain a crosslinking agent. When the adhesive composition contains a crosslinking agent, the cohesive force of the adhesive layer is improved by crosslinking the acrylic copolymer in the adhesive composition to form an adhesive layer. be able to.
架橋剤としては、多官能イソシアネート化合物〔トリレンジイソシアネート（ＴＤＩ）、４，４´－ジフェニルメタンジイソシアネート（ＭＤＩ）、ヘキサメチレンジイソシアネート、キシリレンジイソシアネート、メタキシリレンジイソシアネート、１，５－ナフタレンジイソシアネート、水素化ジフェニルメタンジイソシアネート、水素化トリレンジイソシアネート、水素化キシリレンジイソシアネート、イソホロンジイソシアネート等〕や多官能エポキシ化合物、アセチルアセトン金属塩などが挙げられる。また、例えば、日本ポリウレタン工業株式会社製のコロネート（登録商標）ＨＬ、コロネートＬ、コロネートＥＨ、三菱ガス化学株式会社製のＴＥＴＲＡＤ－Ｘ、（登録商標）、ＴＥＴＲＡＤ－Ｃ（登録商標）、ナーセム（登録商標）アルミニウムなどの市販品を架橋剤とすることができる。架橋剤は、単独で、又は２種類以上を用いてもよい。 As a crosslinking agent, polyfunctional isocyanate compounds [tolylene diisocyanate (TDI), 4,4'-diphenylmethane diisocyanate (MDI), hexamethylene diisocyanate, xylylene diisocyanate, metaxylylene diisocyanate, 1,5-naphthalene diisocyanate, hydrogenated diphenylmethane diisocyanate, hydrogenated tolylene diisocyanate, hydrogenated xylylene diisocyanate, isophorone diisocyanate, etc.], polyfunctional epoxy compounds, and acetylacetone metal salts. In addition, for example, Coronate (registered trademark) HL, Coronate L, Coronate EH manufactured by Nippon Polyurethane Industries, Ltd., TETRAD-X, (registered trademark), TETRAD-C (registered trademark), Naseem (trademark) manufactured by Mitsubishi Gas Chemical Co., Ltd. A commercially available product such as aluminum (registered trademark) can be used as a crosslinking agent. The crosslinking agent may be used alone or in combination of two or more.
本発明において用いられる粘着剤組成物が架橋剤を含有する場合、架橋剤の含有量は、アクリル共重合体１００質量部に対して、好ましくは０．０１～１質量部、より好ましくは０．０３～０．５質量部、特に好ましくは０．０４～０．１質量部である。 When the adhesive composition used in the present invention contains a crosslinking agent, the content of the crosslinking agent is preferably 0.01 to 1 part by mass, more preferably 0.01 to 1 part by mass, based on 100 parts by mass of the acrylic copolymer. 0.03 to 0.5 parts by weight, particularly preferably 0.04 to 0.1 parts by weight.
本発明において用いられる粘着剤組成物に架橋剤を含有させる場合、架橋剤は、当該粘着組成物に予め含有させていてもよく、当該粘着剤組成物を支持体に塗工する直前又は塗工中の粘着組成物に添加してもよい。 When a crosslinking agent is contained in the adhesive composition used in the present invention, the crosslinking agent may be included in the adhesive composition in advance, and the crosslinking agent may be added to the adhesive composition immediately before or after coating the adhesive composition on a support. It may be added to the adhesive composition therein.
（液状可塑剤）
本発明に係る医療用貼付材の粘着剤層に含有される液状可塑剤は、粘着剤層を可塑化してソフト感を付与するものであり、これにより皮膚刺激性が低減される。本発明において用いられる粘着剤組成物が含有する液状可塑剤は、室温で液状であり、当該粘着剤組成物が含有するアクリル系共重合体と相溶である、分子量が３５０～５５０の脂肪酸エステルである。当該粘着剤組成物に含有されている室温で液状の脂肪酸エステルが、当該粘着剤組成物が含有するアクリル系共重合体と相溶であり、かつ分子量３５０～５５０である単一種の脂肪酸エステルのみであってもよく、２種類以上の脂肪酸エステルを含有していてもよい。室温で液状であり、当該粘着剤組成物が含有するアクリル系共重合体と相溶である脂肪酸エステルが２種類以上含有されている場合、これらの脂肪酸エステルの質量平均分子量が３５０～５５０の範囲内にあればよい。室温で液状であり、大きさが特定の範囲であって、アクリル系共重合体と相溶である脂肪酸エステルを用いることにより、アクリル系共重合体と脂肪酸エステルが均一に混じりあっており、ヒト皮膚への高い粘着力を維持しつつ、皮膚から剥離した際に皮膚への残留が充分に抑えられた粘着剤層が形成される。
(liquid plasticizer)
The liquid plasticizer contained in the adhesive layer of the medical patch according to the present invention plasticizes the adhesive layer and imparts a soft feel, thereby reducing skin irritation. The liquid plasticizer contained in the adhesive composition used in the present invention is a fatty acid ester having a molecular weight of 350 to 550, which is liquid at room temperature and is compatible with the acrylic copolymer contained in the adhesive composition. It is. The fatty acid ester that is liquid at room temperature contained in the adhesive composition is only a single type of fatty acid ester that is compatible with the acrylic copolymer contained in the adhesive composition and has a molecular weight of 350 to 550. or may contain two or more types of fatty acid esters. When the adhesive composition contains two or more types of fatty acid esters that are liquid at room temperature and are compatible with the acrylic copolymer contained in the adhesive composition, the weight average molecular weight of these fatty acid esters is in the range of 350 to 550. It's fine if it's inside. By using a fatty acid ester that is liquid at room temperature, has a specific size range, and is compatible with the acrylic copolymer, the acrylic copolymer and fatty acid ester are uniformly mixed, making it suitable for humans. An adhesive layer is formed that maintains high adhesion to the skin and is sufficiently suppressed from remaining on the skin when removed from the skin.
分子量が３５０～５５０の範囲内である脂肪酸エステルであって、アクリル系共重合体との相溶性が高いものは、充分な可塑性を付与でき、さらに、粘着剤組成物塗工後の乾燥工程等の加熱工程での揮散が無い。このため、分子量が３５０～５５０の範囲内の脂肪酸エステルを液状可塑剤として用いることにより、粘着剤層を形成した場合に適度な皮膚接着性を付与可能であり、かつ剥離時に剥離される角質の面積を抑えることが可能な粘着剤組成物が得られる。 Fatty acid esters having a molecular weight within the range of 350 to 550 and having high compatibility with the acrylic copolymer can impart sufficient plasticity, and can also be used in the drying process after applying the adhesive composition. There is no volatilization during the heating process. Therefore, by using a fatty acid ester with a molecular weight within the range of 350 to 550 as a liquid plasticizer, it is possible to impart appropriate skin adhesion when an adhesive layer is formed, and to reduce the amount of dead skin that is peeled off during peeling. A pressure-sensitive adhesive composition that can reduce the area is obtained.
本発明において用いられる粘着剤組成物は、分子量が３５０～５５０の範囲内の脂肪酸エステルの中でも、少なくとも１個の脂肪酸残基（脂肪酸に由来する残基。具体的には、脂肪酸から水酸基を除いた基）がオレイン酸残基（オレイン酸から水酸基を除いた基）であるオレイン酸エステルを含有することが好ましい。液状可塑剤としてオレイン酸エステル（少なくとも１個のオレイン酸残基を有する脂肪酸エステル）を用いると、本発明において用いられる粘着剤組成物から形成された粘着剤層は、連続貼付時（長期間貼付時）や繰り返し貼付時に皮膚への影響がより低減される。 The adhesive composition used in the present invention contains at least one fatty acid residue (residue derived from a fatty acid. Specifically, a hydroxyl group is removed from a fatty acid and a fatty acid ester having a molecular weight of 350 to 550 is used. It is preferable that the group containing an oleic acid ester is an oleic acid residue (a group obtained by removing a hydroxyl group from oleic acid). When an oleic acid ester (a fatty acid ester having at least one oleic acid residue) is used as a liquid plasticizer, the adhesive layer formed from the adhesive composition used in the present invention can be easily applied during continuous application (long-term application). The effect on the skin is further reduced during repeated application.
オレイン酸エステルとしては、１価アルコールとオレイン酸のエステルであってもよく、多価アルコールとオレイン酸のエステルであってもよい。１価アルコールとしては、カプリルアルコール、ラウリルアルコール、ミリスチルアルコール、セチルアルコール、ステアリルアルコール、イソステアリルアルコール、オレイルアルコール等のアルキルアルコールが挙げられる。多価アルコールとしては、グルセリン、ソルビトール、グリコール等が挙げられる。 The oleic acid ester may be an ester of a monohydric alcohol and oleic acid, or an ester of a polyhydric alcohol and oleic acid. Examples of the monohydric alcohol include alkyl alcohols such as caprylic alcohol, lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, and oleyl alcohol. Examples of polyhydric alcohols include glycerin, sorbitol, glycol, and the like.
多価アルコールとオレイン酸のエステルの場合、多価アルコール中の１個の水酸基のみが脂肪酸とエステル結合していてもよく、２個以上の水酸基が脂肪酸とエステル結合していてもよい。２個以上の水酸基が脂肪酸とエステル結合したオレイン酸エステルの場合、エステル中の脂肪酸残基の一部のみがオレイン酸残基であってもよく、エステル中の全ての脂肪酸残基がオレイン酸残基であってもよい。 In the case of an ester of a polyhydric alcohol and oleic acid, only one hydroxyl group in the polyhydric alcohol may have an ester bond with a fatty acid, or two or more hydroxyl groups may have an ester bond with a fatty acid. In the case of an oleic acid ester in which two or more hydroxyl groups are ester bonded to a fatty acid, only a part of the fatty acid residues in the ester may be oleic acid residues, or all fatty acid residues in the ester may be oleic acid residues. It may be a base.
本発明において用いられる粘着剤組成物が含有する分子量が３５０～５５０の範囲内のオレイン酸エステルとしては、具体的には、オレイン酸オクチル、オレイン酸ラウリル、オレイン酸ミリスチル、オレイン酸セチル、オレイン酸ステアリル、オレイン酸イソステアリル、オレイン酸オレイル、モノオレイン酸グリセリル、モノオレイン酸ソルビタン、ヒマシ油脂肪酸エステル等が挙げられる。これらのオレイン酸エステルは、単独で又は２種以上組み合わせて使用してもよい。本発明において用いられる粘着剤組成物が含有するオレイン酸エステルとしては、モノオレイン酸グリセリル（分子量：３５６．５）、モノオレイン酸ソルビタン（分子量：４２８．６）、オレイン酸オレイル（分子量：５３１）が好ましく、特に、オレイン酸オレイルが特に好ましい。 Specifically, the oleic acid ester having a molecular weight within the range of 350 to 550 contained in the adhesive composition used in the present invention includes octyl oleate, lauryl oleate, myristyl oleate, cetyl oleate, and oleic acid ester. Examples include stearyl, isostearyl oleate, oleyl oleate, glyceryl monooleate, sorbitan monooleate, and castor oil fatty acid ester. These oleic acid esters may be used alone or in combination of two or more. The oleic acid esters contained in the adhesive composition used in the present invention include glyceryl monooleate (molecular weight: 356.5), sorbitan monooleate (molecular weight: 428.6), and oleyl oleate (molecular weight: 531). are preferred, and oleyl oleate is particularly preferred.
本発明において用いられる粘着剤組成物における分子量が３５０～５５０の範囲内のオレイン酸エステルの含有量は、アクリル系共重合体１００質量部に対して、好ましくは１～３５質量部、より好ましくは５～２５質量部である。この含有量が１質量部未満の場合、粘着剤層の可塑化が不充分となって皮膚刺激性を低減することができない場合があり、逆に３５質量部を超える場合、粘着剤が有する凝集力が低下し、剥離時に皮膚への糊残りを生ずる恐れがある。 The content of the oleic acid ester having a molecular weight within the range of 350 to 550 in the adhesive composition used in the present invention is preferably 1 to 35 parts by weight, more preferably 1 to 35 parts by weight, based on 100 parts by weight of the acrylic copolymer. It is 5 to 25 parts by mass. If this content is less than 1 part by mass, the adhesive layer may not be sufficiently plasticized and skin irritation may not be reduced; if it exceeds 35 parts by mass, the adhesive may have agglomerates. The strength may be reduced and adhesive may remain on the skin during peeling.
本発明において用いられる粘着剤組成物におけるオレイン酸エステル以外の脂肪酸エステルであって、分子量が３５０～５５０の範囲内のものとしては、イソステアリン酸イソステアリル（分子量：約５３７）等が挙げられる。 Examples of fatty acid esters other than oleate esters in the adhesive composition used in the present invention having a molecular weight within the range of 350 to 550 include isostearyl isostearate (molecular weight: about 537).
本発明において用いられる粘着剤組成物は、本発明の効果を損なわない限度において、分子量が３５０～５５０の範囲内の脂肪酸エステル以外のその他の液状可塑剤を含有していてもよい。その他の液状可塑剤としては、室温で液状であり、かつアクリル系共重合体と相溶性のある可塑剤であれば特に限定されるものではない。例えば、分子量が３５０未満のオレイン酸エステル、分子量が５５０超のオレイン酸エステル、オレイン酸エステル以外の脂肪酸エステル、脂肪酸エステル以外の液状可塑剤等が挙げられる。脂肪酸エステル以外の液状可塑剤としては、例えば、エチレングリコール、ジエチレングリコール、トリエチレングリコール、ポリエチレングリコール、プロピレングリコール、ポリプロピレングリコール等のグリコール；オリーブ油、ヒマシ油、スクアレン、ラノリン等の油脂；流動パラフィン等の炭化水素類；等が挙げられる。その他、室温で液状の有機溶剤や界面活性剤を用いることもできる。また、粘着剤組成物に含有されている脂肪酸エステル全体として当該粘着剤組成物を構成するアクリル系共重合体と相溶であればよく、当該アクリル系共重合体と不相溶の脂肪酸エステルを含有していてもよい。 The adhesive composition used in the present invention may contain liquid plasticizers other than fatty acid esters having a molecular weight within the range of 350 to 550, as long as the effects of the present invention are not impaired. Other liquid plasticizers are not particularly limited as long as they are liquid at room temperature and are compatible with the acrylic copolymer. Examples include oleic acid esters with a molecular weight of less than 350, oleic acid esters with a molecular weight of more than 550, fatty acid esters other than oleic acid esters, liquid plasticizers other than fatty acid esters, and the like. Examples of liquid plasticizers other than fatty acid esters include glycols such as ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, and polypropylene glycol; fats and oils such as olive oil, castor oil, squalene, and lanolin; carbonized liquid paraffin, etc. Examples include hydrogens; etc. In addition, organic solvents and surfactants that are liquid at room temperature can also be used. In addition, the fatty acid ester contained in the adhesive composition as a whole may be compatible with the acrylic copolymer constituting the adhesive composition, and fatty acid esters that are incompatible with the acrylic copolymer may be May contain.
本発明において用いられる粘着剤組成物が含有する液状可塑剤が、分子量が３５０～５５０の範囲内であり、かつアクリル系共重合体と相溶である脂肪酸エステルのみである場合、本発明において用いられる粘着剤組成物における分子量が３５０～５５０の範囲内の脂肪酸エステルの含有量は、アクリル系共重合体１００質量部に対して、好ましくは１～３５質量部、より好ましくは５～２５質量部である。この含有量が１質量部未満の場合、粘着剤層の可塑化が不充分となって皮膚刺激性を低減することができない場合があり、逆に３５質量部を超える場合、粘着剤が有する凝集力が低下し、剥離時に皮膚への糊残りを生ずる恐れがある。なお、アクリル系共重合体が含有する分子量が３５０～５５０の範囲内であり、かつアクリル系共重合体と相溶である脂肪酸エステルが２種類以上である場合、「粘着剤組成物における分子量が３５０～５５０の範囲内の脂肪酸エステルの含有量」は、分子量が３５０～５５０の範囲内であり、かつアクリル系共重合体と相溶である脂肪酸エステルに該当する脂肪酸エステルの総量を意味する。 When the liquid plasticizer contained in the adhesive composition used in the present invention is only a fatty acid ester having a molecular weight within the range of 350 to 550 and compatible with the acrylic copolymer, the adhesive composition used in the present invention may be used. The content of the fatty acid ester having a molecular weight within the range of 350 to 550 in the adhesive composition is preferably 1 to 35 parts by weight, more preferably 5 to 25 parts by weight, based on 100 parts by weight of the acrylic copolymer. It is. If this content is less than 1 part by mass, the adhesive layer may not be sufficiently plasticized and skin irritation may not be reduced; if it exceeds 35 parts by mass, the adhesive may have agglomerates. The strength may be reduced and adhesive may remain on the skin during peeling. In addition, when the molecular weight of the acrylic copolymer is within the range of 350 to 550 and there are two or more types of fatty acid esters that are compatible with the acrylic copolymer, "the molecular weight in the adhesive composition is "Content of fatty acid ester within the range of 350 to 550" means the total amount of fatty acid esters that have a molecular weight within the range of 350 to 550 and are compatible with the acrylic copolymer.
本発明において用いられる粘着剤組成物に、分子量が３５０～５５０の範囲内であり、かつアクリル系共重合体と相溶である脂肪酸エステルと、その他の液状可塑剤とを含有する場合、本発明において用いられる粘着剤組成物に含まれている液状可塑剤全量に対する、分子量が３５０～５５０の範囲内の脂肪酸エステルの含有量は、５０質量％以上であることが好ましく、６０質量％以上であることがより好ましく、８０質量％以上であることがさらに好ましく、９０質量％以上であることが特に好ましい。また、粘着剤組成物に含まれている液状可塑剤全体の質量平均分子量、特に、室温で液状の脂肪酸エステル全体の質量平均分子量が、３５０～５５０の範囲であることが好ましい。 When the adhesive composition used in the present invention contains a fatty acid ester having a molecular weight within the range of 350 to 550 and which is compatible with the acrylic copolymer and other liquid plasticizer, the present invention The content of fatty acid ester with a molecular weight within the range of 350 to 550 is preferably 50% by mass or more, and 60% by mass or more, based on the total amount of liquid plasticizer contained in the adhesive composition used in The content is more preferably 80% by mass or more, even more preferably 90% by mass or more. Further, it is preferable that the mass average molecular weight of the entire liquid plasticizer contained in the adhesive composition, particularly the mass average molecular weight of the entire fatty acid ester that is liquid at room temperature, is in the range of 350 to 550.
（添加剤）
本発明において用いられる粘着剤組成物は、前記架橋剤の他に、必要に応じて、各種添加剤を含有することができる。当該添加剤としては、薬物、充填剤、酸化防止剤（抗酸化剤、防腐剤）、着色剤、香料、粘着付与剤など、貼付材が備える粘着剤層を形成する粘着剤において慣用されている添加剤を含有することができる。例えば、粘着剤の粘着特性を調整するために、粘着付与剤を配合することができる。粘着付与剤としては、例えば、テルペン系、テルペンフェノール系、クマロンインデン系、スチレン系、ロジン系、キシレン系、フェノール系、石油系などの粘着付与樹脂を挙げることができる。
(Additive)
The pressure-sensitive adhesive composition used in the present invention may contain various additives in addition to the crosslinking agent, if necessary. Such additives include drugs, fillers, antioxidants (antioxidants, preservatives), colorants, fragrances, tackifiers, etc. that are commonly used in adhesives that form the adhesive layer of patch materials. It may contain additives. For example, a tackifier can be added to adjust the adhesive properties of the adhesive. Examples of the tackifier include terpene-based, terpene-phenol-based, coumaron-indene-based, styrene-based, rosin-based, xylene-based, phenol-based, and petroleum-based tackifying resins.
＜医療用貼付材＞
本発明に係る医療用貼付材は、支持体と粘着剤層の積層体を備える。本発明に係る医療用貼付材は、支持体の少なくとも片面に、本発明において用いられる粘着剤組成物からなる粘着剤層を備えることが好ましい。粘着剤層が前記粘着剤組成物により形成されるため、ヒト皮膚への充分な粘着力を維持しつつ、剥離時の角質の剥離面積を抑えることができ、皮膚表面の同じ部位に連続貼付又は繰り返し貼付した際にも皮膚刺激への影響が少ない医療用貼付材が得られる。このため、本発明に係る医療用貼付材は、カテーテル等のチューブ固定用のように皮膚の同じ部位に繰り返し貼付される貼付材や、磁気治療器絆創膏等のような皮膚の特定の部位に連続貼付や繰り返し貼付される貼付材に好適である。
<Medical patch>
The medical patch according to the present invention includes a laminate of a support and an adhesive layer. The medical patch according to the present invention preferably includes a pressure-sensitive adhesive layer made of the pressure-sensitive adhesive composition used in the present invention on at least one side of the support. Since the adhesive layer is formed from the above-mentioned adhesive composition, it is possible to maintain sufficient adhesion to human skin while reducing the area of keratin that is peeled off during peeling, and it is possible to maintain sufficient adhesion to human skin and to suppress the peeling area of the stratum corneum during peeling. A medical patch that has little effect on skin irritation even when repeatedly applied is obtained. For this reason, the medical patch according to the present invention can be used as a patch that is repeatedly applied to the same area of the skin, such as for fixing a tube such as a catheter, or continuously applied to a specific area of the skin, such as a magnetic therapy bandage. Suitable for adhesive materials that are pasted or repeatedly pasted.
（支持体）
本発明に係る医療用貼付材を構成する支持体は、透湿度が５００ｇ／ｍ２・２４ｈ以上のものである。充分な透湿度である支持体を用いることにより、透湿度が充分に高く、皮膚に貼付した際の蒸れが少なく、皮膚刺激や貼付中のかゆみが生じにくい医療用貼付材となる。支持体の透湿度としては、５００ｇ／ｍ２・２４ｈ以上が好ましく、７００ｇ／ｍ２・２４ｈ以上であることがより好ましく、１，０００ｇ／ｍ２・２４ｈ以上であることがさらに好ましく、１，５００ｇ／ｍ２・２４ｈ以上であることがよりさらに好ましく、５，０００ｇ／ｍ２・２４ｈ以上であることが特に好ましい。
(Support)
The support constituting the medical patch according to the present invention has a moisture permeability of 500 g/m 2 ·24 h or more. By using a support with sufficient moisture permeability, a medical patch with sufficiently high moisture permeability, less stuffiness when applied to the skin, and less likely to cause skin irritation or itchiness during application can be obtained. The moisture permeability of the support is preferably 500 g/m 2 ·24 h or more, more preferably 700 g/m 2 ·24 h or more, even more preferably 1,000 g/m 2 ·24 h or more, 1, It is even more preferably 500 g/m 2 ·24 h or more, and particularly preferably 5,000 g/m 2 ·24 h or more.
支持体としては、例えば、含浸紙、コート紙、上質紙、クラフト紙、和紙、グラシン紙等の紙類；ポリエチレンテレフタレートやポリブチレンテレフタレート等のポリエステルフィルム、ポリエチレンやポリプロピレン等のポリオレフィンフィルム、ポリ塩化ビニルフィルム、ポリカーボネートフィルム、ポリウレタンフィルム、セロハンフィルムなどのプラスチックフィルム；発泡体；不織布、織布、編布等の布帛類；これら２種以上の積層体；などが挙げられる。前記布帛類の材質としては、天然素材、合成樹脂素材、再生樹脂材料及びこれら適宜を組み合わせた各種の材料を用いることができ、中でもポリエステル、ポリウレタン、ポリエチレン、ポリプロピレン、ポリアミド、アクリル樹脂等を原料とする不織布、織布、編布等を用いることができる。 Examples of the support include papers such as impregnated paper, coated paper, high-quality paper, kraft paper, Japanese paper, and glassine paper; polyester films such as polyethylene terephthalate and polybutylene terephthalate; polyolefin films such as polyethylene and polypropylene; and polyvinyl chloride. Films, plastic films such as polycarbonate films, polyurethane films, and cellophane films; foams; fabrics such as nonwoven fabrics, woven fabrics, and knitted fabrics; laminates of two or more of these; and the like. As the material of the fabrics, natural materials, synthetic resin materials, recycled resin materials, and various materials that are appropriately combined with these materials can be used. Among them, polyester, polyurethane, polyethylene, polypropylene, polyamide, acrylic resin, etc. are used as raw materials. Nonwoven fabrics, woven fabrics, knitted fabrics, etc. can be used.
本発明に係る医療用貼付材の支持体の透湿度は、５００ｇ／ｍ２・２４ｈ以上である。そのため、当該支持体としては、不織布、織布、編布等の布帛類が好ましい。中でも、皮膚に密着することができ、かつ、皮膚の動きに追随することができる程度の柔軟な材質、そして長時間貼付後において皮膚のかぶれ等の発生を抑制できる材質が好ましく、貼付下の皮膚面の動きに対する追随性に優れる点において、さらには、強度を維持しやすく、自背面接着力がより強くなる点において、織布が好ましい。 The moisture permeability of the support of the medical patch according to the present invention is 500 g/m 2 ·24 h or more. Therefore, as the support, fabrics such as nonwoven fabrics, woven fabrics, and knitted fabrics are preferable. Among these, materials that are flexible enough to adhere closely to the skin and follow the movements of the skin, and materials that can suppress the occurrence of skin irritation after long-term application are preferred. Woven fabric is preferable because it has excellent ability to follow the movement of the surface, can easily maintain strength, and has stronger self-back surface adhesion.
支持体の厚みは、伸び、引張り強さ、作業性などの物理的性質や、貼付時の感触や患部の密閉性等を考慮して適宜選択可能であるが、通常５μｍから１ｍｍ程度である。なお、支持体の厚みが５μｍ～３０μｍ程度とごく薄い場合は、粘着剤層が設けられた支持体の一方側の面とは反対の面（以下、他方側の面という）上に、キャリア層を設けてもよい。 The thickness of the support can be appropriately selected in consideration of physical properties such as elongation, tensile strength, workability, feel during application, sealability of the affected area, etc., and is usually about 5 μm to 1 mm. Note that when the thickness of the support is very thin, about 5 μm to 30 μm, a carrier layer is placed on the opposite surface of the support (hereinafter referred to as the other surface) to the one surface on which the adhesive layer is provided. may be provided.
支持体が布帛類である場合、その厚みは、好ましくは５０μｍ～１ｍｍ、より好ましくは１００μｍ～８００μｍ、更に好ましくは２００μｍ～７００μｍである。また、目付けは、皮膚への追従性の点から、好ましくは４００ｇ／ｍ２以下、より好ましくは３００ｇ／ｍ２以下、さらに好ましくは２５０ｇ／ｍ２以下である。 When the support is a fabric, its thickness is preferably 50 μm to 1 mm, more preferably 100 μm to 800 μm, even more preferably 200 μm to 700 μm. In addition, the basis weight is preferably 400 g/m 2 or less, more preferably 300 g/m 2 or less, still more preferably 250 g/m 2 or less, from the viewpoint of conformability to the skin.
また、支持体がプラスチックフィルムである場合、その厚みは、好ましくは１０μｍ～３００μｍ、より好ましくは１２μｍ～２００μｍ、さらに好ましくは１５μｍ～１５０μｍである。なお、支持体がフィルムである場合は、粘着剤層と支持体の投錨性を向上することを目的に、支持体の一方側の面又は他方側の面、あるいはそれら両面にサンドブラスト処理、コロナ処理等の処理を行なってもよい。 Further, when the support is a plastic film, the thickness thereof is preferably 10 μm to 300 μm, more preferably 12 μm to 200 μm, and even more preferably 15 μm to 150 μm. In addition, when the support is a film, sandblasting or corona treatment is applied to one side of the support, the other side, or both sides in order to improve the anchoring properties of the adhesive layer and the support. Processing such as the following may also be performed.
前記支持体の厚みが５μｍよりも小さいと、粘着テープの強度や取り扱い性が低下して、皮膚への貼付が困難になり、他の部材等との接触によって破れたり、入浴等の水との接触によって短時間で皮膚から剥離したりすることがある。また、支持体の厚みが大きすぎる（１ｍｍより超える）と、粘着テープが皮膚の動きに追随しにくくなり、粘着テープの辺縁部に剥がれるきっかけを形成しやすくなるため、短時間で皮膚から剥離したり、貼付中の違和感が増えたりするおそれがある。 If the thickness of the support is less than 5 μm, the strength and handling properties of the adhesive tape will decrease, making it difficult to apply to the skin, causing it to tear due to contact with other materials, or being exposed to water during bathing, etc. Contact may cause it to peel off from the skin within a short period of time. In addition, if the thickness of the support is too large (more than 1 mm), it will be difficult for the adhesive tape to follow the movement of the skin, and it will be easy to form a trigger for peeling at the edge of the adhesive tape, so it will peel off from the skin in a short time. There is a risk that the product may cause discomfort during application.
（粘着剤層）
粘着剤層は、本発明において用いられる粘着剤組成物を、支持体の表面に所望の厚みとなるように塗工し、乾燥させることにより形成される。粘着剤組成物が架橋剤を含む場合、塗工後に紫外線照射処理等の架橋剤の種類に応じた架橋処理を行う。
(Adhesive layer)
The adhesive layer is formed by applying the adhesive composition used in the present invention to the surface of a support to a desired thickness and drying it. When the adhesive composition contains a crosslinking agent, a crosslinking treatment such as ultraviolet irradiation treatment depending on the type of crosslinking agent is performed after coating.
本発明に係る医療用貼付材における粘着剤層の厚みは、特に限定されるものではなく、好ましくは１～２００μｍ、より好ましくは１０～１００μｍ、さらに好ましくは２０～８０μｍである。粘着力は、粘着剤層の厚みに依存し、粘着剤層の厚みが厚すぎると、粘着力が高くなりすぎ、粘着剤層の厚みが薄すぎると、粘着力が弱くなる。粘着剤層の厚みを前記範囲内とすることで、皮膚に十分な粘着力で粘着できることに加えて、貼付材を皮膚などの微細な凹凸のある被着体表面に沿って密着させることができ、さらに、使用後に剥離した際に皮膚刺激を低く抑えることができる。 The thickness of the adhesive layer in the medical patch according to the present invention is not particularly limited, and is preferably 1 to 200 μm, more preferably 10 to 100 μm, and still more preferably 20 to 80 μm. The adhesive force depends on the thickness of the adhesive layer; if the adhesive layer is too thick, the adhesive force will be too high, and if the adhesive layer is too thin, the adhesive force will be weak. By setting the thickness of the adhesive layer within the above range, in addition to being able to adhere to the skin with sufficient adhesive strength, it is also possible to make the adhesive adhere closely along the surface of the adherend, such as the skin, which has minute irregularities. Furthermore, skin irritation can be suppressed to a low level when peeled off after use.
（キャリア層）
本発明に係る医療用貼付材は、支持体に仮着させてキャリア層を形成させてもよい。例えば、「キャリア層／支持体／粘着剤層／セパレーター層」の積層構成を有する貼付材とすることができる。キャリア層により、支持体の厚さが薄い場合に、支持体の製膜性、貼付材の取扱性、被着体への貼付性を向上させることができる。キャリア層は、貼付材の取扱性を向上させるために設けられるものであるから、貼付材の全面を覆っていても、貼付材の縁部のみを覆っていても、あるいは、格子状などのパターン状に覆っていてもよい。
(Career layer)
The medical patch according to the present invention may be temporarily attached to a support to form a carrier layer. For example, it can be a patch having a laminated structure of "carrier layer/support body/adhesive layer/separator layer". When the thickness of the support is thin, the carrier layer can improve the film-forming properties of the support, the handling properties of the adhesive material, and the adhesion properties to an adherend. The carrier layer is provided to improve the handling of the adhesive material, so it may cover the entire surface of the adhesive material, only the edges of the adhesive material, or may have a pattern such as a grid. It may be covered in a shape.
キャリア層は、例えば、ポリウレタン、ポリエチレン、ポリプロピレン、アイオノマー、ポリアミド、ポリ塩化ビニル、ポリ塩化ビニリデン、エチレン酢酸ビニル共重合体、熱可塑性ポリエステル、ポリテトラフルオロエチレンなどの各種熱可塑性樹脂からなるフィルムを用いて形成することが好ましい。 The carrier layer may be a film made of various thermoplastic resins such as polyurethane, polyethylene, polypropylene, ionomer, polyamide, polyvinyl chloride, polyvinylidene chloride, ethylene vinyl acetate copolymer, thermoplastic polyester, polytetrafluoroethylene, etc. It is preferable to form it by
各種フィルムは、紙にラミネートされた状態のものでもよい。これらのキャリア層は、支持体（例えばポリウレタンエラストマーフィルム）に比べて、厚みが厚いか、腰の強いものとすることが好ましい。キャリア層の厚みは、適宜設定できるが、通常、１０μｍ以上、好ましくは２０μｍ以上であり、その上限値は５００μｍ程度である。 Various films may be laminated onto paper. These carrier layers are preferably thicker or stiffer than the support (eg, polyurethane elastomer film). The thickness of the carrier layer can be set as appropriate, but is usually 10 μm or more, preferably 20 μm or more, and the upper limit thereof is about 500 μm.
（セパレーター層）
本発明に係る医療用貼付材は、支持体層、粘着剤層の他に、通常、粘着剤層を皮膚に貼り付けるときまで、粘着剤層を保護するために、粘着剤層に隣接してセパレーター層が備えられる。
(Separator layer)
In addition to the support layer and the adhesive layer, the medical patch according to the present invention usually has a layer adjacent to the adhesive layer to protect the adhesive layer until the adhesive layer is applied to the skin. A separator layer is provided.
本発明におけるセパレーター層としては、特に限定されず、貼付材の技術分野において、一般に、離型紙、離型フィルム、剥離紙、剥離フィルム、剥離ライナーなどと称して使用されるものを用いることができる。具体的には、例えば、表面をシリコーン処理したポリエチレンテレフタレートフィルム、表面をシリコーン処理したポリエチレンと紙との積層体などが挙げられる。また、セパレーター層は、取扱い性（すなわち、粘着剤層からの剥離性）を向上するために、切れ目を設けてもよく、貼付材より大きな面積に形成し、周縁部に掴み部を設けてもよい。また、セパレーター層は、取扱い性の向上や印刷適性の向上等の目的で、セパレーター層の粘着剤層に対向する面又は粘着剤層の反対側の面に、サンドブラスト処理等による凹凸を設けてもよい。 The separator layer in the present invention is not particularly limited, and those commonly used in the technical field of adhesive materials such as release paper, release film, release paper, release film, release liner, etc. can be used. . Specifically, examples include a polyethylene terephthalate film whose surface has been treated with silicone, and a laminate of polyethylene and paper whose surface has been treated with silicone. In addition, the separator layer may be provided with cuts in order to improve handling properties (i.e., peelability from the adhesive layer), or may be formed to have a larger area than the adhesive material and have gripping portions on the periphery. good. In addition, the separator layer may be provided with unevenness by sandblasting or the like on the surface of the separator layer that faces the adhesive layer or the surface opposite to the adhesive layer for the purpose of improving handleability or printing suitability. good.
セパレーター層の厚みは、適宜設定することができ、特に限定されないが、通常２０μｍ以上、好ましくは４０μｍ以上であり、その上限値は５００μｍ程度である。 The thickness of the separator layer can be set appropriately and is not particularly limited, but is usually 20 μm or more, preferably 40 μm or more, and the upper limit thereof is about 500 μm.
（透湿度）
本発明に係る医療用貼付材は、透湿度が５００ｇ／ｍ２・２４ｈ以上であることが好ましい。当該貼付材は、透湿度が５００ｇ／ｍ２・２４ｈ以上であることで、皮膚に貼付した際の蒸れが少ないため、皮膚刺激や貼付中のかゆみが生じにくい。当該貼付材の透湿度は、７００ｇ／ｍ２・２４ｈ以上であることがより好ましく、１，０００ｇ／ｍ２・２４ｈ以上であることがさらに好ましく、１，５００ｇ／ｍ２・２４ｈ以上であることがよりさらに好ましく、５，０００ｇ／ｍ２・２４ｈ以上であることが特に好ましい。透湿度は高いほど好ましく、好ましい透湿度の上限は特にないが、通常３０，０００ｇ／ｍ２・２４ｈ以下である。なお、本発明において透湿度の測定は、ＪＩＳ Ｚ０２０８のＢ条件に従って、温度４０℃、相対湿度９０％で測定する。すなわち、貼付材の片面側を温度４０℃、相対湿度９０％に調節し、他面側には塩化カルシウム等の吸湿剤を置いて貼付材を通過した水分を吸収させ、吸湿剤の重量変化量を２４時間、１ｍ２当たりに換算して算出する。
(moisture permeability)
The medical patch according to the present invention preferably has a moisture permeability of 500 g/m 2 ·24 h or more. The adhesive material has a moisture permeability of 500 g/m 2 ·24 hours or more, so there is less stuffiness when applied to the skin, so skin irritation and itching during application are less likely to occur. The moisture permeability of the patch is more preferably 700 g/m 2.24 h or more, even more preferably 1,000 g/m 2.24 h or more, and 1,500 g/m 2.24 h or more. is even more preferable, and particularly preferably 5,000 g/m 2 ·24 h or more. The higher the moisture permeability is, the more preferable it is, and there is no particular upper limit to the preferable moisture permeability, but it is usually 30,000 g/m 2 ·24 h or less. In the present invention, moisture permeability is measured at a temperature of 40° C. and a relative humidity of 90% in accordance with B conditions of JIS Z0208. That is, one side of the patch is adjusted to a temperature of 40°C and a relative humidity of 90%, and a moisture absorbent such as calcium chloride is placed on the other side to absorb the moisture that has passed through the patch, and the weight change of the moisture absorbent is determined. Calculated by converting it into 1 m2 for 24 hours.
（粘着力）
本発明に係る医療用貼付材の粘着力は、対ベークライト粘着力（剥離力）として、好ましくは０．５～１２．０Ｎ／２５ｍｍ、より好ましくは２．０～８．０Ｎ／２５ｍｍの範囲内であることが好ましい。医療用貼付材の粘着力がこの範囲内であることにより、本発明に係る医療用貼付材を皮膚表面に貼付した場合、十分な貼付性能を備え、貼付中に位置ずれが生じないとともに、当該貼付材を剥離するときには、皮膚表面を剥離したり、かぶれを発生したりする恐れがない。
(Adhesive force)
The adhesive force of the medical patch according to the present invention is preferably in the range of 0.5 to 12.0 N/25 mm, more preferably 2.0 to 8.0 N/25 mm, as adhesive force to Bakelite (peel force). It is preferable that Since the adhesive force of the medical patch is within this range, when the medical patch according to the present invention is applied to the skin surface, it has sufficient application performance, does not cause positional displacement during application, and does not cause any displacement during application. When removing the patch, there is no risk of peeling off the skin surface or causing a rash.
医療用貼付材の粘着力の測定方法は以下の通りである。すなわち、貼付材を、幅２５ｍｍ×長さ１５ｍｍ以上、好ましくは１００ｍｍの所定の長さに裁断して試験片とする。試験片をベークライト製試験パネルに押しつけて貼着させた後、２ｋｇのローラーで圧着速さ３００ｍｍ／分、圧着回数１往復で貼着させて試験片を調製する。貼着してから２０分間経過した後、ＪＩＳ Ｚ０２３７の引きはがし粘着力試験方法に準拠し、剥離角度１８０°、剥離速度３００ｍｍ／分の条件で、粘着力を測定する。 The method for measuring the adhesive strength of medical patches is as follows. That is, the patch is cut into a predetermined length of 25 mm width x 15 mm length or more, preferably 100 mm to obtain a test piece. A test piece is prepared by pressing and adhering the test piece to a test panel made of Bakelite, and then adhering it with a 2 kg roller at a speed of 300 mm/min and 1 reciprocation of the number of times of crimping. After 20 minutes have passed since pasting, the adhesive strength is measured in accordance with the JIS Z0237 peel-off adhesive strength test method under conditions of a peeling angle of 180° and a peeling speed of 300 mm/min.
（医療用貼付材の製造方法）
本発明に係る医療用貼付材の製造方法は特に限定されない。例えば、いわゆる剥離ライナーとして一般に使用されるセパレーター層の上に、粘着剤溶液を塗布し、乾燥させて粘着剤層を形成する方法を採用することが好ましい。粘着剤層の連続的な形成方法としては、セパレーター層を一方向に走行させながら、その上に粘着剤溶液を塗布し、乾燥させる方法が好ましい。粘着剤を溶融してセパレーター層上に塗工する方法を採用してもよい。また、特定の形状の繰り返しパターンコーティングとすることもできる。
(Method for manufacturing medical patch)
The method for manufacturing the medical patch according to the present invention is not particularly limited. For example, it is preferable to employ a method in which an adhesive solution is applied onto a separator layer generally used as a so-called release liner and dried to form an adhesive layer. As a method for continuously forming the adhesive layer, a method of applying an adhesive solution thereon and drying the separator layer while running the separator layer in one direction is preferred. A method may also be adopted in which the adhesive is melted and applied onto the separator layer. It can also be a repeating pattern coating with a specific shape.
セパレーター層の片面に粘着剤層を形成した積層体と支持体とを、粘着剤層と支持体の表面が密着するように貼り合わせることにより、「支持体／粘着剤層／セパレーター層」の積層構成を有する貼付材を作製することができる。また、支持体の片面に任意層であるキャリア層を形成した積層体の場合、粘着剤層と当該積層体の支持体の表面が密着するように貼り合わせることにより、「キャリア層（任意層）／支持体／粘着剤層／セパレーター層」の積層構成を有する貼付材を作製することができる。 By laminating a laminate with an adhesive layer formed on one side of the separator layer and a support so that the surfaces of the adhesive layer and the support are in close contact, the laminate of "support/adhesive layer/separator layer" is formed. A patch having the following configuration can be produced. In addition, in the case of a laminate in which a carrier layer, which is an optional layer, is formed on one side of a support, by laminating the adhesive layer and the surface of the support of the laminate in close contact, it is possible to / support / adhesive layer / separator layer'' can be produced.
次に実施例を示して本発明をさらに詳細に説明するが、本発明は以下の実施例に限定されるものではない。 EXAMPLES Next, the present invention will be explained in more detail with reference to Examples, but the present invention is not limited to the following Examples.
［実施例１～４、比較例１～７］
各種液状可塑剤を含有する粘着剤組成物を調製し、これで粘着剤層を形成した貼付材について、粘着力とヒト皮膚への影響を調べた。液状可塑剤としては、オレイン酸メチル（分子量：２９６．５）、ミリスチン酸イソプロピル（分子量：２６８．０）、モノオレイン酸グリセリル（分子量：３５６．０）、モノオレイン酸ソルビタン（分子量：４２８．６）、オレイン酸オレイル（分子量：５３１．０）、イソステアリン酸イソステアリル（分子量：５３７．０）、大豆油（分子量：約８８０、ＳＲソイビーン－ＬＱ－（ＪＰ）、クローダジャパン社製）、トリオレイン酸ソルビタン（分子量：９３５．０）、ヒマシ油脂肪酸エステル（分子量：約５００、リックサイザーＣ－１０１、伊藤製油社製）、オレイン酸デシル（分子量：４２２.４）、特殊ヒマシ油系縮合脂肪酸（分子量：８００、ミネラゾール、伊藤製油社製）、を用いた。また、支持体としては、織布（縦糸：コアスパン、横糸：綿、透湿度：２１，０６０ｇ／ｍ２・２４ｈ、目付１５５ｇ／ｍ２）、ウレタン不織布（繊維径：１５μｍ、透湿度：２１，５９０ｇ／ｍ２・２４ｈ、目付６５ｇ／ｍ２）、ポリエチレンフィルム（厚さ：５０μｍ、透湿度：６０ｇ／ｍ２・２４ｈ）を用いた。
[Examples 1 to 4, Comparative Examples 1 to 7]
Adhesive compositions containing various liquid plasticizers were prepared, and the adhesive strength and effect on human skin of patches with adhesive layers formed using these compositions were investigated. Liquid plasticizers include methyl oleate (molecular weight: 296.5), isopropyl myristate (molecular weight: 268.0), glyceryl monooleate (molecular weight: 356.0), and sorbitan monooleate (molecular weight: 428.6). ), oleyl oleate (molecular weight: 531.0), isostearyl isostearate (molecular weight: 537.0), soybean oil (molecular weight: approximately 880, SR Soybean-LQ-(JP), manufactured by Croda Japan), triolein Acid sorbitan (molecular weight: 935.0), castor oil fatty acid ester (molecular weight: approximately 500, Ricksizer C-101, manufactured by Ito Oil Co., Ltd.), decyl oleate (molecular weight: 422.4), special castor oil-based condensed fatty acid ( Molecular weight: 800, Minerazole (manufactured by Ito Oil Co., Ltd.) was used. In addition, as supports, woven fabric (warp: core spun, weft: cotton, moisture permeability: 21,060 g/m 2 24h, basis weight 155 g/m 2 ), urethane nonwoven fabric (fiber diameter: 15 μm, moisture permeability: 21, 590 g/m 2 ·24 h, basis weight 65 g/m 2 ), and polyethylene film (thickness: 50 μm, moisture permeability: 60 g/m 2 ·24 h) were used.
＜サンプル作製＞
まず、粘着剤組成物として、アクリル酸２－エチルヘキシルエステル／酢酸ビニル／アクリル酸＝８５／１１／４（質量比）からなる単量体混合物を共重合反応して得られたアクリル系共重合体の溶液に、アクリル系共重合体１００質量部に対して、表１～３に記載の液状可塑剤を表１に示す質量部となるように混合し、さらに架橋剤としてＴｅｔｒａｄ－Ｘ（三菱ガス化学社製）０．０６質量部を混合し、均一な粘着剤組成物の溶液を調製した。
この粘着剤組成物の溶液を、セパレーター（シリコーン処理ポリラミ剥離紙）の剥離処理面に、乾燥後の厚みが３８μｍになるよう塗布、乾燥して粘着剤層を形成した。この粘着剤層を、表１～３に記載の支持体に貼り合わせて貼付材を作製した。
<Sample preparation>
First, as an adhesive composition, an acrylic copolymer obtained by copolymerizing a monomer mixture consisting of acrylic acid 2-ethylhexyl ester/vinyl acetate/acrylic acid = 85/11/4 (mass ratio). The liquid plasticizers listed in Tables 1 to 3 were mixed with the solution of 100 parts by mass of the acrylic copolymer in the mass parts shown in Table 1, and Tetrad-X (Mitsubishi Gas (manufactured by Kagaku Co., Ltd.) was mixed to prepare a uniform solution of the adhesive composition.
A solution of this adhesive composition was applied to the release-treated surface of a separator (silicone-treated polylaminated release paper) to a thickness of 38 μm after drying, and dried to form an adhesive layer. This adhesive layer was bonded to the supports listed in Tables 1 to 3 to produce adhesive patches.
＜ヒト皮膚への粘着力の測定＞
サイズ１５ｍｍ×７０ｍｍの被験サンプルを、ヒト被験者の前腕部に貼付した。貼付から２４時間後に、インストロン型引張試験機を用いて、剥離速度１００ｍｍ／分、剥離角度９０°の条件で粘着力（Ｎ／１５ｍｍ）を測定した（ｎ＝８）。剥離は、小指側から親指側に行った。測定結果を表１～３に示す。
<Measurement of adhesion to human skin>
A test sample with a size of 15 mm x 70 mm was applied to the forearm of a human subject. 24 hours after application, the adhesive strength (N/15 mm) was measured using an Instron type tensile tester at a peeling rate of 100 mm/min and a peeling angle of 90° (n=8). Peeling was performed from the little finger side to the thumb side. The measurement results are shown in Tables 1 to 3.
＜角質剥離面積率の測定＞
前記の粘着力測定において剥離された後の各被験サンプルを、カチオン染色（ゲンチアナバイオレット：１．０％、ブリリアントグリーン：０．５％、蒸留水：９８．５％）で染色した後、流水下で洗浄した。染色後の被験サンプルを顕微鏡（ＶＨＸ－１０００：ＶＨ－Ｚ１００ＵＲ、キーエンス社製）下で撮像し、得られた画像を画像処理装置（Ｗｉｎ ＲＯＯＦ、三谷商事社製）で画像解析することによって、各被験サンプルに付着している角質細胞の面積を測定した。各被験サンプルについて、３視野の角質細胞付着面積率（［角質細胞付着面積］／［被験サンプルの表面積］×１００（％））を算出し、この平均値を各被験サンプルの角質剥離面積率とした（ｎ＝８）。測定結果を表１～３に示す。
<Measurement of exfoliated area rate>
After being peeled off in the above adhesive force measurement, each test sample was stained with cationic staining (gentian violet: 1.0%, brilliant green: 0.5%, distilled water: 98.5%), and then dyed under running water. Washed with. The stained test sample was imaged under a microscope (VHX-1000: VH-Z100UR, manufactured by Keyence Corporation), and the obtained image was analyzed using an image processing device (Win ROOF, manufactured by Mitani Shoji Co., Ltd.). The area of corneocytes attached to the test sample was measured. For each test sample, calculate the keratinocyte adhesion area rate ([keratinocyte adhesion area]/[surface area of test sample] x 100 (%)) in the three fields of view, and calculate the average value as the keratin exfoliation area rate for each test sample. (n=8). The measurement results are shown in Tables 1 to 3.
＜粘着剤の残留＞
前記の粘着力測定において、各被験サンプルを剥離した後の皮膚表面に、粘着剤が残ったかどうかを目視で確認した（ｎ＝８）。結果を表１～３に示す。表中、「×」は剥離時に粘着剤が皮膚に残ったことを、「〇」は剥離時に粘着剤が皮膚に残らなかったことを示す。
<Adhesive residue>
In the above adhesive force measurement, it was visually confirmed whether any adhesive remained on the skin surface after each test sample was peeled off (n=8). The results are shown in Tables 1 to 3. In the table, "x" indicates that the adhesive remained on the skin during peeling, and "〇" indicates that no adhesive remained on the skin during peeling.
＜繰り返し前腕部貼付試験＞
被験サンプルを、ヒト皮膚表面に貼付し、２４時間ごとに剥離し、１時間後の皮膚反応を確認した後に、新たな同種の被験サンプルを同部位に貼付する繰り返し前腕部貼付試験（最大７日間、１試験区当たり７枚の被験サンプルを使用）を行った（ｎ＝９）。皮膚反応は、剥離１時間後及び２４時間後（試験終了日）に、５：反応なし、４：軽い紅斑あり、３：紅斑あり、２：紅斑＋浮腫あり、１：紅斑＋浮腫＋丘疹あり、又は小水疱あり、０：大水疱あり、として評価した。結果を表１～３に示す。
<Repeated forearm patch test>
A test sample is applied to the human skin surface, peeled off every 24 hours, and after confirming the skin reaction 1 hour later, a new test sample of the same type is applied to the same site (repeated forearm application test (up to 7 days). , using 7 test samples per test section) (n=9). Skin reactions were observed 1 hour and 24 hours after peeling (on the test end day): 5: no reaction, 4: slight erythema, 3: erythema, 2: erythema + edema, 1: erythema + edema + papules. , or there were small blisters, and 0: there were large blisters. The results are shown in Tables 1 to 3.
支持体が同一である実施例１～６及び比較例１～８で比較すると、各被験サンプルのヒト皮膚への粘着力は、脂肪酸エステルをアクリル系共重合体１００質量部に対して、１０質量部又は２０質量部配合した被験サンプル（比較例２～３、実施例１～６、比較例５～８）では、脂肪酸エステルを配合していない被験サンプル（比較例１）と比べて高い数値であり、脂肪酸エステルを配合することにより、粘着力を高めることができた。脂肪酸エステルをアクリル系共重合体１００質量部に対して３０質量部配合した被験サンプル（比較例４）では、剥離時に粘着剤残留が発生した。これは、液状可塑剤の含有量が多く、粘着剤層が柔らかくなりすぎたためと推察された。一方で、アクリル系共重合体との相溶性が劣るオレイン酸デシルを選択した被験サンプル（比較例７）は、粘着剤の残留試験において、粘着剤残留が発生し、医療用貼付材として問題があるものであった。 Comparing Examples 1 to 6 and Comparative Examples 1 to 8, in which the supports were the same, it was found that the adhesion of each test sample to human skin was as follows: 10 parts by mass of fatty acid ester per 100 parts by mass of acrylic copolymer. The test samples (Comparative Examples 2 to 3, Examples 1 to 6, Comparative Examples 5 to 8) containing 20 parts by mass or 20 parts by mass showed higher values compared to the test sample containing no fatty acid ester (Comparative Example 1). By incorporating fatty acid ester, the adhesive strength could be increased. In the test sample (Comparative Example 4) in which 30 parts by mass of fatty acid ester was blended with 100 parts by mass of the acrylic copolymer, adhesive residue was generated upon peeling. This was presumed to be because the content of liquid plasticizer was high and the adhesive layer became too soft. On the other hand, in the test sample (Comparative Example 7) in which decyl oleate, which has poor compatibility with acrylic copolymers, was selected, adhesive residue occurred in the adhesive residual test, causing problems as a medical patch. It was something.
各被験サンプルの角質剥離面積率は、分子量が３５０～５５０の範囲でアクリル酸系共重合体との相溶性が良好な脂肪酸エステルを配合した被験サンプル（実施例１～６）では、比較例１と比べて角質剥離面積率が４０％前後と十分に低くなった。これに対して、分子量が当該範囲から外れている脂肪酸エステルを配合した被験サンプル（比較例３、比較例５、６、８）では、角質剥離面積率が５０％以上であり、低減効果が小さいことが確認できた。また、液状可塑剤として分子量が当該範囲から外れているミリスチン酸イソプロピル（分子量：２６８．０）を１５質量部と、分子量が当該範囲内であるオレイン酸オレイル（分子量：５３１．０）５質量部とを含有しており、液状可塑剤の質量平均分子量が３３３．８［（２６８．０×１５＋５３１．０×５）／（１５＋５）］である比較例３の被験サンプルは、分子量が当該範囲から外れている脂肪酸エステルのみを配合した被験サンプルと同様に、角質剥離面積率が５０％以上であり、低減効果が小さかった。 The exfoliation area ratio of each test sample was as follows: Comparative Example 1 Compared to the above, the exfoliated area ratio was sufficiently low at around 40%. On the other hand, in the test samples (Comparative Example 3, Comparative Examples 5, 6, and 8) containing fatty acid esters with molecular weights outside the range, the exfoliation area ratio was 50% or more, and the reduction effect was small. This was confirmed. In addition, as a liquid plasticizer, 15 parts by mass of isopropyl myristate (molecular weight: 268.0) whose molecular weight is outside the range, and 5 parts by mass of oleyl oleate (molecular weight: 531.0) whose molecular weight is within the range. The test sample of Comparative Example 3, in which the mass average molecular weight of the liquid plasticizer is 333.8 [(268.0×15+531.0×5)/(15+5)], has a molecular weight within the range. Similar to the test sample containing only the fatty acid ester, the exfoliation area ratio was 50% or more, and the reduction effect was small.
皮膚反応は、分子量が３５０～５５０の範囲内であってアクリル系共重合体との相溶性が良好な脂肪酸エステルを配合した被験サンプル（実施例１～６）は、経時推移でほとんど皮膚状態が低下することなく維持できていることが確認できた。また、試験終了日の剥離２４時間後においても、赤みが残った被験者が少ないことが確認できた。一方、支持体のみ異なる被験サンプル（実施例３、７、比較例９）を比較すると、透湿度が５００ｇ／ｍ２・２４ｈ以上であるウレタン不織布を支持体とした実施例７は、透湿度が５００ｇ／ｍ２・２４ｈ以上である織布を支持体とした実施例３と遜色の無い評価結果であったが、透湿度が６０ｇ／ｍ２・２４ｈであるポリエチレンフィルムを支持体とした比較例９では、角質薄利面積率は低いものの、ヒト皮膚粘着力が大きく低下し、皮膚反応も強いものであった。これらの結果より、透湿度が５００ｇ／ｍ２・２４ｈ以上である織布又は不織布を支持体とし、アクリル系共重合体からなる粘着剤層に対して、アクリル系共重合体との相溶性が良好な分子量３５０～５５０の脂肪酸エステルを適切な量配合することにより、高い粘着力を維持しつつ、皮膚の同じ部位に連続貼付又は繰り返し貼付した際にも皮膚刺激が低い粘着剤層を形成できることが明らかである。 Regarding skin reactions, test samples (Examples 1 to 6) containing fatty acid esters with a molecular weight in the range of 350 to 550 and good compatibility with acrylic copolymers showed almost no skin condition over time. It was confirmed that it was maintained without any decline. Furthermore, it was confirmed that few subjects remained with redness even 24 hours after removal on the test completion day. On the other hand, when comparing test samples (Examples 3, 7, and Comparative Example 9) that differ only in support, Example 7, whose support was a urethane nonwoven fabric with a moisture permeability of 500 g/m 2.24 h or more, had a lower moisture permeability. The evaluation results were comparable to those of Example 3 in which a woven fabric with a moisture permeability of 500 g/m 2 · 24 h or more was used as a support, but a comparative example in which a polyethylene film with a moisture permeability of 60 g/m 2 · 24 h was used as a support In case 9, although the keratin thinning area ratio was low, the human skin adhesion was greatly reduced and the skin reaction was strong. From these results, it was found that the compatibility with the acrylic copolymer was determined by using a woven fabric or nonwoven fabric with a water vapor permeability of 500 g/m 2 · 24 h or more as a support, and using an adhesive layer made of an acrylic copolymer. By blending an appropriate amount of a fatty acid ester with a good molecular weight of 350 to 550, it is possible to form an adhesive layer that maintains high adhesive strength and has low skin irritation even when applied continuously or repeatedly to the same area of the skin. is clear.
Claims (7)
前記粘着剤層が、（メタ）アクリル酸アルキルエステルを主成分とした共重合体と、室温で液状の前記共重合体と相溶する脂肪酸エステルとを含有する粘着剤組成物からなり、
前記粘着剤組成物に含有されている前記脂肪酸エステルの質量平均分子量が３５０～５５０であり、
前記粘着剤組成物は、前記共重合体１００質量部に対して、前記脂肪酸エステルを５～２５質量部含有しており、
前記支持体は、紙類、発泡体、布帛類又はこれらの組み合わせからなり、前記布帛類は、不織布（ただしポリエステル不織布を除く）、織布又は編布であり、
前記支持体の透湿度が５００ｇ／ｍ２・２４ｈ以上であり、
前記医療用貼付材はチューブ固定用である、医療用貼付材。 A medical patch comprising a laminate of a support and an adhesive layer,
The adhesive layer is made of an adhesive composition containing a copolymer mainly composed of an alkyl (meth)acrylate ester and a fatty acid ester that is liquid at room temperature and is compatible with the copolymer,
The weight average molecular weight of the fatty acid ester contained in the adhesive composition is 350 to 550,
The adhesive composition contains 5 to 25 parts by mass of the fatty acid ester based on 100 parts by mass of the copolymer,
The support is made of paper, foam, fabric, or a combination thereof, and the fabric is a nonwoven fabric (excluding polyester nonwoven fabric), a woven fabric, or a knitted fabric,
The moisture permeability of the support is 500 g/m 2 · 24 h or more ,
The medical patch is for fixing a tube .
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2019/049904 WO2020261609A1 (en) | 2018-06-29 | 2019-12-19 | Medical patch material |
| KR1020217037657A KR20220027057A (en) | 2018-06-29 | 2019-12-19 | medical patch |
| CN201980096526.5A CN113853414B (en) | 2018-06-29 | 2019-12-19 | Medical adhesive material |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018124441 | 2018-06-29 | ||
| JP2018124441 | 2018-06-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020006166A JP2020006166A (en) | 2020-01-16 |
| JP7369552B2 true JP7369552B2 (en) | 2023-10-26 |
Family
ID=69149973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019122202A Active JP7369552B2 (en) | 2018-06-29 | 2019-06-28 | medical patch |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP7369552B2 (en) |
| KR (1) | KR20220027057A (en) |
| CN (1) | CN113853414B (en) |
| WO (1) | WO2020261609A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022092090A1 (en) | 2020-10-29 | 2022-05-05 | 日東電工株式会社 | Resin for adhesive sheet, and adhesive sheet |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002065841A (en) | 2000-09-01 | 2002-03-05 | Nitto Denko Corp | Skin-stickable adhesive composition, skin-stickable adhesive tape or sheet |
| JP2005089438A (en) | 2003-09-19 | 2005-04-07 | Kosumedei:Kk | Adhesive composition for skin and self-adhesive tape or sheet for skin |
| WO2007126067A1 (en) | 2006-04-28 | 2007-11-08 | Lion Corporation | Nonaqueous pressure-sensitive adhesive composition, patches and process for production of patches |
| JP2007296120A (en) | 2006-04-28 | 2007-11-15 | Lion Corp | Sticking agent |
| JP2009155306A (en) | 2007-12-28 | 2009-07-16 | Lion Corp | Transdermal patch |
| JP2018023784A (en) | 2016-08-09 | 2018-02-15 | 日東電工株式会社 | Adhesive skin patch and wound body of adhesive skin patch |
-
2019
- 2019-06-28 JP JP2019122202A patent/JP7369552B2/en active Active
- 2019-12-19 WO PCT/JP2019/049904 patent/WO2020261609A1/en active Application Filing
- 2019-12-19 CN CN201980096526.5A patent/CN113853414B/en active Active
- 2019-12-19 KR KR1020217037657A patent/KR20220027057A/en not_active Application Discontinuation
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002065841A (en) | 2000-09-01 | 2002-03-05 | Nitto Denko Corp | Skin-stickable adhesive composition, skin-stickable adhesive tape or sheet |
| JP2005089438A (en) | 2003-09-19 | 2005-04-07 | Kosumedei:Kk | Adhesive composition for skin and self-adhesive tape or sheet for skin |
| WO2007126067A1 (en) | 2006-04-28 | 2007-11-08 | Lion Corporation | Nonaqueous pressure-sensitive adhesive composition, patches and process for production of patches |
| JP2007296120A (en) | 2006-04-28 | 2007-11-15 | Lion Corp | Sticking agent |
| JP2009155306A (en) | 2007-12-28 | 2009-07-16 | Lion Corp | Transdermal patch |
| JP2018023784A (en) | 2016-08-09 | 2018-02-15 | 日東電工株式会社 | Adhesive skin patch and wound body of adhesive skin patch |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113853414B (en) | 2023-12-08 |
| CN113853414A (en) | 2021-12-28 |
| KR20220027057A (en) | 2022-03-07 |
| JP2020006166A (en) | 2020-01-16 |
| WO2020261609A1 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6358874B2 (en) | Acrylic adhesive composition and adhesive tape or sheet | |
| JP4755284B2 (en) | Adhesive material | |
| EP1671660B1 (en) | Hot melt adhesives for medical application | |
| TWI352727B (en) | ||
| KR20150108771A (en) | Adhesive tape or sheet for skin | |
| EP1867347B1 (en) | Medical adhesive and medical adhesive tape or sheet | |
| JP2002069405A (en) | Adhesive composition and adhesive tape or sheet | |
| JP2010082102A (en) | Adhesive tape or sheet for application to skin, and method for producing the same | |
| JP7369552B2 (en) | medical patch | |
| JP6478334B2 (en) | Adhesive material | |
| JP2007289672A (en) | Adhesive composition for stratum corneum exfoliation, and adhesive sheet for stratum corneum exfoliation | |
| JPH0228978B2 (en) | ||
| JP2002065841A (en) | Skin-stickable adhesive composition, skin-stickable adhesive tape or sheet | |
| JP4912159B2 (en) | Adhesive composition for skin application and skin application material | |
| JP6214529B2 (en) | Sebum-absorbing patch and method for producing the same | |
| JP2009261727A (en) | Medical self-adhesive composite and self-adhesive tape or sheet | |
| JP2000230157A (en) | Stretchable adhesive tape or sheet | |
| JP2005314618A (en) | Skin-patch pressure-sensitive adhesive composition and skin patch material given by using the skin-patch pressure-sensitive adhesive composition | |
| CN113316437A (en) | Skin adhesive material | |
| JP4970888B2 (en) | Medical adhesive and medical adhesive tape or sheet | |
| JPH09206369A (en) | Skin adhesive material and first aid adhesive bandage | |
| JP2024094833A (en) | Medical patches | |
| JP5596365B2 (en) | Exfoliating adhesive sheet | |
| TW202320724A (en) | Adhesive skin patch material | |
| JP2016084444A (en) | Acrylic adhesive less in keratin detachment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190726 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230307 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230501 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230824 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230901 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231003 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231016 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7369552 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |